Transcept Pharmaceuticals to Present at Two Upcoming Investor Conferences

POINT RICHMOND, Calif., Feb. 5, 2013 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, announced today that Transcept management is scheduled to present a general corporate overview at the following investor conferences.

BIO CEO and Investor Conference in New York
February 12, 2013
2:30 p.m. ET

Leerink Swann Global Healthcare Conference in New York
February 14, 2013
9:00 a.m. ET

A live audio webcast of the presentations will be available in the investor relations section of the Transcept website at www.transcept.com. Replays will be available there for approximately 30 days following the events.

About Transcept Pharmaceuticals

Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Intermezzo® (zolpidem tartrate) sublingual tablet C-IV is the first FDA approved Transcept product. Purdue Pharma holds commercialization and development rights for Intermezzo in the United States. For further information about Transcept, please visit www.transcept.com. For information about Intermezzo, please visit www.MyIntermezzo.com.

SOURCE Transcept Pharmaceuticals, Inc.

RELATED LINKS
http://www.transcept.com